中国血液流变学杂志
中國血液流變學雜誌
중국혈액류변학잡지
CHINESE JOURNAL OF HEMORHEOLOGY
2001年
1期
34-36
,共3页
洛伐他汀%弹性酶%高脂血症%临床研究
洛伐他汀%彈性酶%高脂血癥%臨床研究
락벌타정%탄성매%고지혈증%림상연구
目的研究中剂量洛伐他汀对原发性高脂血症的治疗效果。方法按照随机单盲对照法把患者分为2组,在控制饮食的基础上,治疗组61例口服洛伐他汀每晚20mg,对照组口服弹性酶600ag,tid,均8周为1个疗程。结果洛伐他汀组治疗前后血脂(mmol/L)水平自身对比:TC、TG、LDL-C、VLDL-C分别从6.86±0.99、2.04±1.04、5.17±1.01、0.46±0.42降至4.61±0.82、1.31±0.63、3.00±0.81及0.27±0.13(均P<0.001),HDL-C从1.19±0.38升至1.32±0.39(P<0.05),致粥样硬化指数从4.76降至2.49。弹性酶组,代(mmol/L)从6.15±0.76降至5.77±0.80(P<0.01),LDL-C(mmol/L)从4.54±0.76降至4.21±0.78(P<0.05),而对TG、VLDL-C、HDL-C及致粥样硬化指数无明显影响。两组调脂疗效比较:洛伐他汀降低TC、TG的总有效率分别为96.7%和75.4%,升高HDL-C总有效率63.9%;而弹性酶降低TC、TG的总有效率均为36.7%,升高HDL-C总有效率为23.3%,两组相比均P<0.00l。两药对肝、肾功能及血糖无明显影响。结论洛伐他汀每日20mg,剂量适宜,调脂作用理想而全面,疗效可靠,副作用轻微。
目的研究中劑量洛伐他汀對原髮性高脂血癥的治療效果。方法按照隨機單盲對照法把患者分為2組,在控製飲食的基礎上,治療組61例口服洛伐他汀每晚20mg,對照組口服彈性酶600ag,tid,均8週為1箇療程。結果洛伐他汀組治療前後血脂(mmol/L)水平自身對比:TC、TG、LDL-C、VLDL-C分彆從6.86±0.99、2.04±1.04、5.17±1.01、0.46±0.42降至4.61±0.82、1.31±0.63、3.00±0.81及0.27±0.13(均P<0.001),HDL-C從1.19±0.38升至1.32±0.39(P<0.05),緻粥樣硬化指數從4.76降至2.49。彈性酶組,代(mmol/L)從6.15±0.76降至5.77±0.80(P<0.01),LDL-C(mmol/L)從4.54±0.76降至4.21±0.78(P<0.05),而對TG、VLDL-C、HDL-C及緻粥樣硬化指數無明顯影響。兩組調脂療效比較:洛伐他汀降低TC、TG的總有效率分彆為96.7%和75.4%,升高HDL-C總有效率63.9%;而彈性酶降低TC、TG的總有效率均為36.7%,升高HDL-C總有效率為23.3%,兩組相比均P<0.00l。兩藥對肝、腎功能及血糖無明顯影響。結論洛伐他汀每日20mg,劑量適宜,調脂作用理想而全麵,療效可靠,副作用輕微。
목적연구중제량락벌타정대원발성고지혈증적치료효과。방법안조수궤단맹대조법파환자분위2조,재공제음식적기출상,치료조61례구복락벌타정매만20mg,대조조구복탄성매600ag,tid,균8주위1개료정。결과락벌타정조치료전후혈지(mmol/L)수평자신대비:TC、TG、LDL-C、VLDL-C분별종6.86±0.99、2.04±1.04、5.17±1.01、0.46±0.42강지4.61±0.82、1.31±0.63、3.00±0.81급0.27±0.13(균P<0.001),HDL-C종1.19±0.38승지1.32±0.39(P<0.05),치죽양경화지수종4.76강지2.49。탄성매조,대(mmol/L)종6.15±0.76강지5.77±0.80(P<0.01),LDL-C(mmol/L)종4.54±0.76강지4.21±0.78(P<0.05),이대TG、VLDL-C、HDL-C급치죽양경화지수무명현영향。량조조지료효비교:락벌타정강저TC、TG적총유효솔분별위96.7%화75.4%,승고HDL-C총유효솔63.9%;이탄성매강저TC、TG적총유효솔균위36.7%,승고HDL-C총유효솔위23.3%,량조상비균P<0.00l。량약대간、신공능급혈당무명현영향。결론락벌타정매일20mg,제량괄의,조지작용이상이전면,료효가고,부작용경미。
Objective To investigate the effect of mean - dose Lovastatin in the treatment of essential hyperlipidemia. Methods 91 cases were randomly single- blindly assigned into tested(n = 61) and contral group (n = 30), Besides the controlling of diet, patients in the tested were treated with Lovastatin 20 rng, orally,qn;while subjects in the control group with Elastase 600mg tid, for the course of 8 weeks. Results After 8 weeks of treatment, compared with itself in the tested group, the levels of TC、 TG、 LDL - C、 VLDL - C decreased from 6.86 ± 0.99(mmol/L) to 4.61 ±0.82、2.04± 1.04 to 1.31 ±0.63、5.17 ± 1.01 to 3.00±0.81、0.46 ± 0.42 to 0.27 ± 0.13 respectively, all P < 0.001; HDL- C rised from 1.19 ± 0.38 to 1.32 ± 0.39, P < 0.05; AI decreased from 4.76 to 2.49. There were significant differences(P < 0. 001 ) between the groups. There were no obvious influences on functions of liver and kidney, level of blood sugar. Conclusion 20 mg/d for Lovastatin is a proper dose, the efficacy of regulating lipicls is ideal and all - rounded, side effectsare relatively slight.